TW202233666A - 減少人類對象中之tau的方法 - Google Patents

減少人類對象中之tau的方法 Download PDF

Info

Publication number
TW202233666A
TW202233666A TW110139444A TW110139444A TW202233666A TW 202233666 A TW202233666 A TW 202233666A TW 110139444 A TW110139444 A TW 110139444A TW 110139444 A TW110139444 A TW 110139444A TW 202233666 A TW202233666 A TW 202233666A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
chain variable
days
Prior art date
Application number
TW110139444A
Other languages
English (en)
Chinese (zh)
Inventor
溫迪 加爾彭
馬丁 提姆斯
湯姆 雅各布斯
帕沙 南迪
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202233666A publication Critical patent/TW202233666A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW110139444A 2020-10-26 2021-10-25 減少人類對象中之tau的方法 TW202233666A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
US63/105,804 2020-10-26

Publications (1)

Publication Number Publication Date
TW202233666A true TW202233666A (zh) 2022-09-01

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110139444A TW202233666A (zh) 2020-10-26 2021-10-25 減少人類對象中之tau的方法

Country Status (11)

Country Link
US (1) US20220127345A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232155A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023546504A (cg-RX-API-DMAC7.html)
KR (1) KR20230093499A (cg-RX-API-DMAC7.html)
CN (1) CN116916955A (cg-RX-API-DMAC7.html)
AU (1) AU2021367878A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199806A1 (cg-RX-API-DMAC7.html)
IL (1) IL302386A (cg-RX-API-DMAC7.html)
MX (1) MX2023004831A (cg-RX-API-DMAC7.html)
TW (1) TW202233666A (cg-RX-API-DMAC7.html)
WO (1) WO2022090158A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
JP7379764B1 (ja) 2022-08-09 2023-11-15 レール・リキード-ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 空気分離装置および空気分離方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CN107095846A (zh) * 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP3551655A2 (en) * 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
CN117205311A (zh) * 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
WO2019171258A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
US20230075314A1 (en) * 2019-04-29 2023-03-09 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
JP2023546503A (ja) * 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ.ベー. 抗タウ抗体の安全な投与方法

Also Published As

Publication number Publication date
EP4232155A1 (en) 2023-08-30
AU2021367878A1 (en) 2023-06-22
US20220127345A1 (en) 2022-04-28
WO2022090158A1 (en) 2022-05-05
JP2023546504A (ja) 2023-11-02
KR20230093499A (ko) 2023-06-27
CA3199806A1 (en) 2022-05-05
MX2023004831A (es) 2023-07-12
CN116916955A (zh) 2023-10-20
IL302386A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7241058B2 (ja) 抗N3pGluアミロイドベータペプチド抗体およびその使用
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
CN106390107B (zh) 病理tau蛋白的免疫靶向
TWI705824B (zh) 治療阿茲海默症之方法
US20230123110A1 (en) High dose treatments for alzheimer's disease
TW201900682A (zh) 抗phf-tau抗體及其用途
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
HK40100364A (en) Methods of reducing tau in human subjects
JP2024509956A (ja) 抗N3pGluアミロイドベータ抗体及びその使用
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
CN116829582A (zh) 安全施用抗Tau抗体的方法
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
HK40100358A (en) Method of safe administration of anti-tau antibody
HK1261507A1 (en) High dose treatments for alzheimer's disease